The combination of STING agonists and atezolizumab inhibits breast cancer 4T1 cell growth in mic by increasing the levels of TNF-α, IFN-β, IL-10, and IFN-γ in surrounding blood and tumor masses (P < 0.01). The gene discussed is STING1; the disease is neoplasm.